Hear.com Horizon Go IX vs Lexie B3

The Hear.com Horizon Go IX is a premium prescription behind-the-ear hearing aid released in 2024, priced at $6,500. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.4/5, ranking #19 among 39 prescription hearing aids tested. Speech performance is a clear strength for the Horizon Go IX. It scores 4.0/5 in speech-in-quiet conditions—0.64 points above the category average—delivering strong audibility in conversational settings. Speech-in-noise performance also exceeds the category average by 0.46 points, though at 2.6/5 the absolute score remains mixed, meaning challenging listening environments may still pose difficulties. Own-voice comfort is the device's most notable weakness, scoring just 1.8/5—a low result that falls 0.90 points below the category average. Users sensitive to how their own voice sounds may find this limiting. Feedback handling scores 4.4/5, which is strong in absolute terms, though slightly below the category average of 4.72/5. Music streaming performance is essentially average at 2.7/5. At this price point, shoppers face stiff competition. Several alternatives in the same premium tier—including the Phonak Sphere Infinio, Oticon Intent, and Widex Allure RIC 440—deliver higher overall scores. Devices like the Rexton Reach R-Li T80 at Costco offer comparable or better sound performance at lower prices. The Horizon Go IX is best suited for users who prioritize speech clarity and have access to this product through hear.com's network, but those flexible on brand should compare alternatives before committing.

The Lexie B3 is a mid-priced OTC hearing aid available at $999 that achieves an A grade with a SoundScore of 4.7/5 in our lab testing, ranking #1 among 65 OTC hearing aid devices tested. This behind-the-ear style device delivers category-leading performance across multiple metrics. Speech clarity is a standout strength. In our lab testing, the Lexie B3 scores an excellent 4.5/5 for speech in quiet, measuring 1.73 points above the OTC category average. Speech in noise performance scores 2.5/5—above the category average by 1.02 points, though only mixed in absolute terms at 2.5/5. This pattern reflects the broader challenge OTC devices face in noisy environments while still positioning the B3 as a top performer relative to its category. Music streaming quality is solid at 3.3/5, outperforming the category average by 1.38 points. Own-voice comfort scores a solid 3.0/5, sitting 0.49 points above average. Feedback handling is excellent at 4.6/5, essentially matching the already-strong category average. The Lexie B3 is best suited for consumers seeking top-tier OTC sound performance without prescription hearing aid costs. Those who prioritize speech clarity in quieter settings will find particular value here. Budget-conscious shoppers may want to consider alternatives like the RxEars Rxi, which offers strong performance at a lower price point.